Open AccessABO-incompatible Living Donor Liver Transplantation With Rituximab and Total Plasma Exchange Does Not Increase Hepatocellular Carcinoma Recurrence
Author(s) -
Jong Man Kim,
Choon Hyuck David Kwon,
Seok Joo Han,
Jeejin Yoo,
Kyunga Kim,
Dong Hyun Sinn,
Gyu Seong Choi,
David A. Gerber,
Hiroto Egawa,
Suk Koo Lee
Publication year - 2018
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000002154
Subject(s) - abo blood group system , hepatocellular carcinoma , medicine , rituximab , gastroenterology , liver transplantation , perioperative , carcinoma , surgery , transplantation , lymphoma
ABO-incompatible (ABO-I) living donor liver transplantation (LDLT) has a high success rate. This study compares hepatocellular carcinoma (HCC) recurrence in ABO-I LDLT with that in ABO-compatible (ABO-C) LDLT and explores the effects of rituximab prophylaxis and total plasma exchange on HCC recurrence after LDLT.